NewsBenzingaReported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Benzinga 2026.10.12 08:05 (GMT+0) Open on Benzinga Other news 'Europe’s Top Carriers Explore Satellite Group to Fend Off SpaceX' - Bloomberg HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target AI Boom Hits a Power Wall: Microsoft Walks Away From Nscale's UK Data Center Deal
Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN
